General Description
Grepafloxacin Hydrochloride is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive, Gram-negative, and atypical respiratory pathogens. Its fluorine substituent at the C-6 position and piperazinyl ring at C-7 confer enhanced activity against Streptococcus pneumoniae and improved tissue penetration compared to earlier fluoroquinolones. It was developed specifically for respiratory tract infections.
Mechanism of Action
Grepafloxacin Hydrochloride inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. By forming a ternary complex with the enzyme and DNA, it prevents DNA supercoiling and strand separation, resulting in irreversible DNA damage and bacterial cell death. Its enhanced activity against Streptococcus pneumoniae is attributed to its improved binding affinity for pneumococcal topoisomerase IV.
Application
Grepafloxacin Hydrochloride is indicated for the treatment of community-acquired respiratory tract infections including acute exacerbations of chronic bronchitis, community-acquired pneumonia, and bacterial sinusitis caused by susceptible organisms.